🔴 BreakingDrug approvalRSSApr 3
FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
The FDA has approved a new treatment called Kresladi for a rare immune system disorder called Leukocyte Adhesion Deficiency Type I (LAD-I). This treatment works by using gene therapy, which means it fixes the faulty gene that causes the disease. This is the first gene therapy approved for this specific condition, giving patients with LAD-I a new treatment option.
WHY IT MATTERSPatients with severe LAD-I now have access to the first FDA-approved gene therapy for their condition, which could potentially offer a cure rather than just managing symptoms.